PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB

被引：0
|
作者：
Mian, M.
Pescosta, N. [1 ]
Luminari, S. [2 ]
Badiali, S. [2 ]
Marcheselli, L. [2 ]
Patriarca, F. [3 ]
Zambello, R. [4 ]
Mondello, P. [5 ]
Pascarella, A. [6 ]
Marabese, A.
Pitini, V. [5 ]
Cortelazzo, S. [7 ]
机构：
[1] Hosp Bolzano, Bolzano, Italy
[2] Univ Modena & Reggio Emilia, Dept Hematol & Oncol, Modena, Italy
[3] Azienda Osped Univ, Udine, Italy
[4] Univ Padua, Sch Med, Padua, Italy
[5] Univ Messina, Messina, Italy
[6] Osped Angelo, Venice, Mestre, Italy
[7] Humanitas Gavazzeni Canc Ctr, Bergamo, Italy
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P1007
引用
收藏
页码：382 / 383
页数：2
相关论文
共 50 条
  • [1] PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB
    Mian, M.
    Pescosta, N.
    Luminari, S.
    Badiali, S.
    Marcheselli, L.
    Patriarca, F.
    Zambello, R.
    Mondello, P.
    Pascarella, A.
    Pitini, V.
    Cortelazzo, S.
    [J]. HAEMATOLOGICA, 2014, 99 : 637 - 637
  • [2] Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib
    Mian, Michael
    Pescosta, Norbert
    Badiali, Stefania
    Cappelletto, Paola Cristina
    Marcheselli, Luigi
    Luminari, Stefano
    Patriarca, Francesca
    Zambello, Renato
    Pascarella, Anna
    Tagariello, Giuseppe
    Marabese, Alessandra
    Mondello, Patrizia
    Billio, Atto
    Cortelazzo, Sergio
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (05) : 944 - 947
  • [3] A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Lee, Hans C.
    Shah, Jatin J.
    Feng, Lei
    Morphey, Ashley
    Johnson, Ralph J.
    Wesson, Emily T.
    Wang, Michael L.
    Alexanian, Raymond
    Thomas, Sheeba K.
    Orlowski, Robert Z.
    Weber, Donna M.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (12) : E319 - E322
  • [4] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    Offidani, M.
    Corvatta, L.
    Maracci, L.
    Liberati, A. M.
    Ballanti, S.
    Attolico, I.
    Caraffa, P.
    Alesiani, F.
    di Toritto, T. Caravita
    Gentili, S.
    Tosi, P.
    Brunori, M.
    Derudas, D.
    Ledda, A.
    Gozzetti, A.
    Cellini, C.
    Malerba, L.
    Mele, A.
    Andriani, A.
    Galimberti, S.
    Mondello, P.
    Pulini, S.
    Coppetelli, U.
    Fraticelli, P.
    Olivieri, A.
    Leoni, P.
    [J]. BLOOD CANCER JOURNAL, 2013, 3 : e162 - e162
  • [5] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    M Offidani
    L Corvatta
    L Maracci
    A M Liberati
    S Ballanti
    I Attolico
    P Caraffa
    F Alesiani
    T Caravita di Toritto
    S Gentili
    P Tosi
    M Brunori
    D Derudas
    A Ledda
    A Gozzetti
    C Cellini
    L Malerba
    A Mele
    A Andriani
    S Galimberti
    P Mondello
    S Pulini
    U Coppetelli
    P Fraticelli
    A Olivieri
    P Leoni
    [J]. Blood Cancer Journal, 2013, 3 : e162 - e162
  • [6] Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory multiple myeloma: A phase I/II trial.
    Berenson, J. R.
    Yellin, O.
    Bessudo, A.
    Boccia, R.
    Noga, S.
    Gravenor, D.
    Patel-Donnelly, D.
    Siegel, R. S.
    Kewalramani, T.
    Gorak, E. J.
    Swift, R.
    Bensen-Kennedy, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide
    I-Jun Lau
    Dean Smith
    Robin Aitchison
    Norbert Blesing
    Pamela Roberts
    Andrew Peniket
    Kwee Yong
    Neil Rabin
    Karthik Ramasamy
    [J]. Annals of Hematology, 2015, 94 : 643 - 649
  • [8] Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide
    Lau, I-Jun
    Smith, Dean
    Aitchison, Robin
    Blesing, Norbert
    Roberts, Pamela
    Peniket, Andrew
    Yong, Kwee
    Rabin, Neil
    Ramasamy, Karthik
    [J]. ANNALS OF HEMATOLOGY, 2015, 94 (04) : 643 - 649
  • [9] A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
    Richardson, Paul G.
    Xie, Wanling
    Jagannath, Sundar
    Jakubowiak, Andrzej
    Lonial, Sagar
    Raje, Noopur S.
    Alsina, Melissa
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Munshi, Nikhil C.
    Mazumder, Amitabha
    Vesole, David H.
    Kaufman, Jonathan L.
    Colson, Kathleen
    McKenney, Mary
    Lunde, Laura E.
    Feather, John
    Maglio, Michelle E.
    Warren, Diane
    Francis, Dixil
    Hideshima, Teru
    Knight, Robert
    Esseltine, Dixie-Lee
    Mitsiades, Constantine S.
    Weller, Edie
    Anderson, Kenneth C.
    [J]. BLOOD, 2014, 123 (10) : 1461 - 1469
  • [10] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Yasuo Mori
    Ilseung Choi
    Goichi Yoshimoto
    Tsuyoshi Muta
    Satoshi Yamasaki
    Kazuki Tanimoto
    Tomohiko Kamimura
    Hiromi Iwasaki
    Ryosuke Ogawa
    Koichi Akashi
    Toshihiro Miyamoto
    [J]. International Journal of Hematology, 2020, 111 : 673 - 680
12345